Asia Pacific is Projected to Grow at the Highest CAGR in Bovine Serum Albumin Market

Posted on 2021-04-01 by MarketsandMarkets in Internet & Online // 0 Comments

The global bovine serum albumin market is projected to grow from USD 254.8 million in 2019 to USD 304.2 million by 2025, at a CAGR of 3.0%. The global market is growing due to changing consumer preferences for a protein-rich diet and high demand from the life sciences industry.

Download PDF Brochure

Bovine serum albumin (BSA) or Fraction V is a major plasma protein found in bovine blood. It aids in maintaining the pH levels of blood. It is a significant by-product of the meat industry and is majorly extracted from the fetal blood serum. BSA is purified from the serum by way of different purification methods such as cold-organic solvent fractionation, heat shock, and ion-exchange chromatography.

It is also found in milk and whey proteins in varying proportions. This usually occurs due to the leakage of protein from blood serum into the milk as a part of the secretion from mammary glands. BSA is used extensively in various immunology, biochemistry, and biotechnology applications. It is also used in different cell culture applications for protein supplementation and as a small molecule carrier. Some of the significant industries that demand BSA include the pharmaceutical, diagnostic, feed, and food industries.

The Asia Pacific region holds a range of opportunities for pharmaceutical firms and multinational drugmakers. In the Asia Pacific region, China is the largest market for pharmaceutical products. With the growing interest in health and welfare, the demand for pharmaceutical products is growing. This would help drive the growth of BSA in this region.

The North America region accounted for the largest share in the global market. The growing livestock sector, the rising demand for red meat & its products, and the increasing rate of cattle slaughtering drive the growth of the market in the North American region.

Make an Inquiry

Leading companies are Thermo Fisher Scientific (US), Bio-Rad Laboratories, Inc (US), Merck KGAA (Germany), Itoham Yonekyu Holdings Inc (Japan), Proliant Biologicals (US), Kraeber & Co Gmbh (Germany), Rockland Immunochemicals Inc (US), Rocky mountain biologicals (US), BelHealth investment partners, LLC (US), Bio-Techne Corporation (US), Prospec-Tany Technogene Ltd (Israel), LGC Group (UK), Promega Corporation (US), Biological Industries (Israel), and Serion GmbH (Germany).

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledgestore” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Matched content

Editor’s pick